Vimarsana
Biggest News Aggregation in the World

Distinguish Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Distinguish Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Distinguish Study Today - Breaking & Trending Today

Leap Therapeutics Reports Third Quarter 2023 Financial Results - Vimarsana News

Leap Therapeutics Reports Third Quarter 2023 Financial Results

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

Leap Therapeutics Reports Second Quarter 2023 Financial Results - Vimarsana News

Leap Therapeutics Reports Second Quarter 2023 Financial Results

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results - Vimarsana News

Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting - Vimarsana News

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...

Leap Therapeutics Reports First Quarter 2022 Financial Results - Vimarsana News

Leap Therapeutics Reports First Quarter 2022 Financial Results

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...